Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Anna C Pavlick, BSN, MSc, DO, MBA
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Douglas Laux, MD MSRecruiting - Weill Cornell Medicine/newyork-Presbyterian Hospital
New York, New York, United States
Anna Pavlick, D.O.Recruiting - University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
Randal Kimple, MD, PhDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Aug 2023
- Primary completion
- 31 Dec 2028
- Completion
- 31 Dec 2028
- Last update posted
- 22 Apr 2026
- Registered enrollment
- 18
- Registry id
- NCT05583708
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.